Cyclic GMP-AMP synthase expression is enhanced in systemic sclerosis-associated interstitial lung disease and stimulates inflammatory myofibroblast activation
European Respiratory Journal · 2025
DOI: 10.1183/13993003.01564-2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, 2025. Verfasst von Sheeline Yu und 26 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Myofibroblasts, Nucleotidyltransferases, Lung Diseases, Interstitial. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NIAMS NIH HHS, Yale Physician Scientist Award.
Abstract (Originalsprache)
Objective
The lungs of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) contain inflammatory myofibroblasts that arise in association with fibrotic stimuli and perturbed innate immunity. The cytosolic DNA-binding receptor cyclic GMP-AMP synthase (cGAS) is implicated in inflammation and fibrosis, but its involvement in SSc-ILD remains unknown. We examined cGAS expression, activity and therapeutic potential in SSc-ILD using human biospecimens, cultured fibroblasts, precision-cut lung slices and a well-accepted animal model.
Methods
Expression and localisation of cGAS, cytokines and type 1 interferons were evaluated in SSc‑ILD lung tissues, bronchoalveolar lavage fluid and isolated lung fibroblasts. CGAS activation was assessed in a publicly available SSc-ILD single-cell RNA-sequencing dataset. Production of cytokines, type 1 interferons and α-smooth muscle actin elicited by transforming growth factor-β1 or local substrate stiffness was measured in normal human lung fibroblasts via quantitative reverse transcription PCR, ELISA and immunofluorescence. Small molecule cGAS inhibition was tested in cultured fibroblasts, human precision-cut lung slices and the bleomycin pulmonary fibrosis model.
Results
SSc-ILD lung tissue and bronchoalveolar lavage fluid were enriched for cGAS, cytokines and type 1 interferons. The cGAS pathway showed constitutive activation in SSc-ILD fibroblasts and was inducible in normal human lung fibroblasts by transforming growth factor-β1 or mechanical stimuli. In these settings, and in precision-cut lung slices, cGAS expression was paralleled by the production of cytokines, type 1 interferons and α-smooth muscle actin, which was mitigated by a small molecule cGAS inhibitor. These findings were recapitulated in the bleomycin mouse model. Conclusion cGAS signalling contributes to pathogenic inflammatory myofibroblast phenotypes in SSc‑ILD. Inhibiting cGAS or its downstream effectors represents a novel therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Yale School of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, New Haven, CT, USA.
- Yale School of Medicine, Department of Internal Medicine, Section of Rheumatology, Allergy, and Immunology, New Haven, CT, USA.
- University of Michigan, Department of Internal Medicine, Division of Rheumatology, Ann Arbor, MI, USA.
- Medical University of South Carolina, Department of Medicine, Charleston, SC, USA.
- C. Ryu and E.L. Herzog contributed equally to this work.
- Yale School of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, New Haven, CT, USA erica.herzog@yale.edu.
ORCID-Profile: Jana Zielonka, William Odell, Maor Sauler, Jose L Gomez
Förderung
- NHLBI NIH HHS
- NIAMS NIH HHS
- Yale Physician Scientist Award
- Boehringer Ingelheim
- Wit Family Distinguished Scholar
- Pulmonary Fibrosis Foundation
- The National Institutes of Health
Zitieren
APA
Yu, S., Hu, B., Sun, Y., Peng, X. Y., Lee, C. J., Woo, S., McGovern, J., Zielonka, J., Saber, T., Ghincea, A., Gandhi, S., Walia, A., Pivarnik, T., Ishikawa, G., Shao, S., Sun, H., Gunes, B. I., Kujawski, S., Perez, S., …, & Herzog, E. L. (2025). Cyclic GMP-AMP synthase expression is enhanced in systemic sclerosis-associated interstitial lung disease and stimulates inflammatory myofibroblast activation. European Respiratory Journal. https://doi.org/10.1183/13993003.01564-2024
Vancouver
Yu S, Hu B, Sun Y, Peng XY, Lee CJ, Woo S, et al. Cyclic GMP-AMP synthase expression is enhanced in systemic sclerosis-associated interstitial lung disease and stimulates inflammatory myofibroblast activation. European Respiratory Journal. 2025. doi:10.1183/13993003.01564-2024
BibTeX
@article{Yu2025,
author = {Yu, Sheeline and Hu, Buqu and Sun, Ying and Peng, Xue Yan and Lee, Chris J and Woo, Samuel and McGovern, John and Zielonka, Jana and Saber, Tina and Ghincea, Alexander and Gandhi, Shifa and Walia, Anjali and Pivarnik, Taylor and Ishikawa, Genta and Shao, Shuai and Sun, Huanxing and Gunes, Baran Ilayda and Kujawski, Sophia and Perez, Stephanie and Odell, William and Hinchcliff, Monique and Varga, John and Feghali-Bostwick, Carol and Sauler, Maor and Gomez, Jose L and Ryu, Changwan and Herzog, Erica L},
title = {Cyclic GMP-AMP synthase expression is enhanced in systemic sclerosis-associated interstitial lung disease and stimulates inflammatory myofibroblast activation},
journal = {European Respiratory Journal},
year = {2025},
doi = {10.1183/13993003.01564-2024}
}
EUVIMED